Just got back from IR:

The patent application is filed in China, Hong Kong, and Taiwan (among other places).  It contain claims for the use of compounds (including RVX-208) for the treatment of diseases related to the complement cascade.

Regarding your first question, we don't comment on other company's materials, made at a point in time, including those of a major investor. Resverlogix would likely initiate further Phase 3 clinical development in 2020; more information to be disclosed as known and as appropriate.